Axinn Successfully Advocates for Preservation of 180-Day Marketing Exclusivity for Carvedilol ER
April 13, 2018
Axinn successfully advocated that FDA should preserve the 180-day marketing exclusivity period relating to a generic version of SmithKline’s Coreg CR (carvedilol phosphate extended-release capsules) even though it took the ANDA applicant over 10 years to obtain tentative approval of its product. Through a series of correspondence submitted to FDA over the course of a number of years, Axinn successfully convinced FDA that the 180-day exclusivity period was not forfeited by Mutual Pharmaceutical Company (now Sun Pharma) because of a change in the approval requirements for the product.
Click here to read FDA's decision and here to read press coverage on FDA Law Blog.
To subscribe to our publications, click here.
Featured Insights
Featured Insights
NBA CLS 39th Annual Corporate Counsel Conference
Sponsorship
Antitrust
New Frontiers of Antitrust – 16th Annual International Conference of Concurrences Review
Speaking Engagement
Antitrust
GCR Live Global: Navigating the Future of Antitrust 2026
Speaking Engagement
Antitrust
Stakeholders 25th Annual CYOC Career Development Conference
Sponsorship
Antitrust
American Investment Council’s General Counsel Day
Speaking Engagement
Antitrust
Informa 34th Annual Advanced EU Brussels Conference
Speaking Engagement
Antitrust
Kisaco Research Pharma and Biotech Patent Litigation Summit 2025
Speaking Engagement
Intellectual Property
GCR Live: Women in Antitrust 2025
Speaking Engagement
Antitrust
Global Legal Group Global Class Actions Symposium 2025
Speaking Engagement
Litigation & Trials
Biosimilar Approval Pathway Changes Sponsors Need to Monitor
Media Mentions
Intellectual Property
